University of Toronto

Universitéde Montreal

Mount Sinai Hospital Corporation

Sinai Health System

Ontario Institute for Cancer Research (oicr) and Sinai Health System

Frank Sicheri

Sachdev Singh Sidhu

Wei Zhang

Gennady Poda

Daniel Durocher

Hugo Lavoie

Ganna Posternak

Malha Sahmi

Marc Therrien

Marella Canny

Thanashan Rajakulendran

The present application relates to novel compounds of Formula (I) containing a E3 ubiquitin ligase binding moiety linked to a Raf protein kinase binding moiety. The present application also includes methods and uses of the compounds, for example, for inhibiting and/or degrading V600E mutant B-Raf. I

Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses

53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.

Ubiquitin variants and uses therof as 53BP1 inhibitors

Disclosed herein are biosensors useful for detecting the dimerization of RAF and/or KSR polypeptides. These biosensors comprise fusion proteins comprising RAF and/or KSR proteins fused to bioluminescent or fluorescent proteins. Also disclosed are methods of using the biosensors to detect and measure the dimerization of RAF/RAF and RAF/KSR polypeptides by resonance energy transfer such as BRET or FRET, for example to screen for inhibitors of dimerization.

Biosensor for detecting RAF/KSR family kinase dimerization and uses thereof

Growing community of inventors

Toronto, Canada

Frank Sicheri